Caroline Brard

Phase II and biomarker study of programmed cell death protein 1 inhibitor nivolumab and metronomic cyclophosphamide in paediatric relapsed/refractory solid tumours: Arm G of AcSé-ESMART, a trial of the European Innovative Therapies for Children With Cancer Consortium

Claudia Pasqualini, Jonathan Rubino, Caroline Brard et al. · European Journal of Cancer · 2021 · 56 citations · Full text

Medicine, Oncology, Pharmacology +17

Sarcome-13/OS2016 trial protocol: a multicentre, randomised, open-label, phase II trial of mifamurtide combined with postoperative chemotherapy for patients with newly diagnosed high-risk osteosarcoma

Caroline Brard, Sophie Piperno‐Neumann, Jessy Delaye et al. · BMJ Open · 2019 · 40 citations · Full text

Medicine, Oncology, Pharmacology +17

First-in-child phase I/II study of the dual mTORC1/2 inhibitor vistusertib (AZD2014) as monotherapy and in combination with topotecan-temozolomide in children with advanced malignancies: arms E and F of the AcSé-ESMART trial

Raphael J. Morscher, Caroline Brard, Pablo Berlanga et al. · European Journal of Cancer · 2021 · 37 citations · Full text

Medicine, Oncology, Pharmacology +15

Real world prospective experience of axitinib in metastatic renal cell carcinoma in a large comprehensive cancer centre

Margarida Matias, Gwénaël Le Teuff, Laurence Albigès et al. · European Journal of Cancer · 2017 · 27 citations

Medicine, Oncology, Pharmacology +14

Personalized treatment according to geriatric assessment in first-line recurrent and/or metastatic (R/M) head and neck squamous cell cancer (HNSCC) patients aged 70 or over: ELAN (ELderly heAd and Neck cancer) FIT and UNFIT trials

J. Guigay, A. Aupérin, C. Mertens et al. · Annals of Oncology · 2019 · 21 citations

Medicine, Geriatric Medicine, Oncology +16